ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,923.43
1.64%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Genmab AS (GMAB)

  7. Genmab AS (GMAB) Noticias

GMAB Genmab AS

29.73
2.01 (7.25%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Genmab AS GMAB NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
2.01 7.25% 29.73 18:05:20
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
29.73 29.46 29.92 29.72 27.72
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202417:40BWFDA Grants Full Approval for TIVDAK® to Treat Recurrent or..
03/4/202400:35BWGenmab to Broaden and Strengthen Oncology Portfolio with..
11/3/202412:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/3/202412:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/3/202412:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/3/202416:04EDGAR2Form 144 - Report of proposed sale of securities
29/2/202410:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/2/202410:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202415:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202406:45BWU.S. FDA Accepts for Priority Review the Supplemental..
26/2/202411:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/2/202409:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/2/202415:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/2/202410:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/2/202414:42EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/2/202412:49EDGAR2Form 20-F - Annual and transition report of foreign private..
14/2/202411:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/2/202405:45BWTisotumab Vedotin Marketing Authorization Application..
31/1/202410:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202408:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202406:45DJNPfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval
09/1/202405:45BWTIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics..
03/1/202407:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202310:46EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/12/202311:00BWNew Pivotal Data for Bispecific Antibody Epcoritamab..
01/12/202312:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/11/202306:00BWGenmab Announces Positive Regulatory Updates for Epcoritamab..
21/11/202315:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/11/202309:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202311:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202310:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202308:05BWGenmab Announces Multiple Abstracts to be Presented at the..
22/10/202309:30BWTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged..
17/10/202307:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202309:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/9/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/9/202307:53EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/9/202307:50DJNAbbVie, Genmab Get Conditional Europe OK of Tepkinly..
25/9/202306:45BWGenmab Announces European Commission Approval of TEPKINLY®..
25/9/202304:55BWEPKINLY™ (epcoritamab) Approved by Japan Ministry of Health,..
13/9/202308:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202314:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202308:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/9/202314:00BWSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv)..
16/8/202312:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/8/202314:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202310:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/7/202308:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/7/202303:30BWGenmab Announces AbbVie Receives Positive CHMP Opinion for..
20/7/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Su Consulta Reciente

NASDAQ
GMAB
Genmab AS
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados